此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

The Role of Endothelial Dysfunction in Adult Polycystic Kidney Disease

Endothelial Dysfunction in Autosomal Dominant Polycystic Kidney Disease

This pilot study will compare endothelial function in patients with ADPKD with matched healthy volunteers and normotensive chronic kidney disease stage 1 & 2 patients. Patients will undergo a single assessment of endothelial function and measurement of plasma and urine levels of biomarkers of endothelial function.

研究概览

详细说明

Following recruitment we will record the following baseline demographics; age, gender, smoking status, body mass index, medical history.

Participants will undergo a noninvasive vascular assessment, venepuncture and will provide a urine sample.This will be done during a single visit to the CRF.

Noninvasive vascular assessment will consist of:

  1. Peripheral Arterial Tonometry This will be measured using the EndoPAT system (Itamar Medical)

    Endothelial shear stress flow stimulus will be provided by inflation of a blood pressure cuff around the upper non-dominant arm to suprasystolic pressure (but <300mmHg) for 5 minutes. Following release of the cuff the resulting digital microcirculation vasodilatory response to ischaemic hyperaemia, quantified as the pulse wave amplitude, will be monitored over 5 minutes. The peak pulse wave amplitude measured at 90-150s post cuff deflation relative to baseline will be indexed to the changes in the opposite arm to give the reactive hyperaemia index. This measure of endothelial function constitutes the outcome measure.

  2. Blood Pressure Assessment Brachial artery blood pressure will be measured in the left arm in the supine position using an automated device (Dinamap) and in accordance with the clinical research facility SOP.
  3. Blood samples and urine samples

Samples for plasma will be centrifuged and stored at -80C. Biochemical analysis will be performed by the laboratory of the STH NHS Trust for standard tests and by validated assays for non-routine markers (as detailed below) in the Academic Nephrology Unit.

Participants will be asked to collect a 24h urine sample from the day before the study visit and to provide a spot urine sample on the day. This will be analysed at the laboratory of the STH NHS Trust.

Biochemical Analysis

Serum samples will be analyzed for Full blood count, Urea, Electrolytes, Glucose, Insulin, Lipid Profile, Homocysteine, (Hs) CRP and Creatinine Levels.

Serum and plasma will also be stored for future analysis of relevant biomarkers of endothelial function or nitric oxide metabolism as indicated by preliminary results.

Urine samples will be analysed initially for protein creatinine ratio (PCR). The rest will be frozen for future analysis of urinary biomarkers of endothelial function or nitric oxide metabolism.

研究类型

观察性的

注册 (实际的)

40

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 50年 (成人)

接受健康志愿者

是的

有资格学习的性别

全部

取样方法

非概率样本

研究人群

Normotensive ADPKD patients with well preserved GFR (>60ml/min) ie those with Stage 1 or 2 Chronic Kidney Disease recruited from a specialist PKD clinic. Healthy controls will be recruited matched to age, sex, body mass index (BMI) and eGFR of the ADPKD patients.

描述

Inclusion Criteria:

  • Age >18yrs, <50yrs
  • Able to understand spoken/written English sufficiently to give informed consent and to take part in clinical assessment
  • Clinical diagnosis of ADPKD
  • eGFR >60ml/min/1.73m2

Exclusion Criteria:

  • No history of cardiovascular disease or hypertension
  • Not diabetic
  • Not smoking
  • Not breastfeeding
  • Not pregnant
  • Not taking any regular medication (except oral contraceptives)
  • No musculoskeletal conditions contraindicating inflation of a blood pressure cuff to suprasystolic pressures around the forearm (as part of EndoPAT measurements)
  • Not morbidly obese: BMI<35 (May contribute to endothelial dysfunction)
  • eGFR <60ml/min/1.73m2

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

队列和干预

团体/队列
干预/治疗
控件
健康志愿者
This will be measured using the EndoPAT system (Itamar Medical)
ADPKD
ADPKD patients
This will be measured using the EndoPAT system (Itamar Medical)

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Reactive hyperemia index (RHI)
大体时间:Baseline
EndoPAT values (Endoscore)
Baseline

次要结果测量

结果测量
措施说明
大体时间
Systolic and diastolic Blood pressure
大体时间:Baseline
mm Hg
Baseline
Proteinuria
大体时间:Baseline
Protein creatinine ratio
Baseline

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Albert Ong、STH
  • 研究主任:Timothy Chico、STH

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2011年7月25日

初级完成 (实际的)

2018年12月31日

研究完成 (实际的)

2018年12月31日

研究注册日期

首次提交

2019年7月15日

首先提交符合 QC 标准的

2019年7月15日

首次发布 (实际的)

2019年7月17日

研究记录更新

最后更新发布 (实际的)

2019年7月17日

上次提交的符合 QC 标准的更新

2019年7月15日

最后验证

2019年7月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅